Market Place
Sourcing Support
Rheos Medicines Receives FDA “Study May Proceed” Letter to Initiate PI Study
20 Jul 2022 //
BUSINESSWIRE
Rheos Medicines CSO Dania Rabah to Deliver Keynote Address at AAPS
12 May 2022 //
BUSINESSWIRE
Rheos Medicines Announces Publication of New Data to Support Targeting MALT1
09 May 2022 //
BUSINESSWIRE
Rheos Medicines Announces New Scientific Advisory Board Members
14 Apr 2022 //
BUSINESSWIRE
Rheos Appoints K. Leftheris, Ph.D., as SVP and N. Uddin, Pharm.D., as VP
14 Apr 2022 //
BUSINESSWIRE
Rheos Presents New Data Supporting MALT1 Inhibition as Novel Strategy for GvHD
13 Dec 2021 //
BUSINESSWIRE
Rheos Medicines to Present Data at ASH 2021 for MALT1 Inhibition
04 Nov 2021 //
BUSINESSWIRE
Rheos Medicines Presents Data Demonstrating Potential of MALT1 Inhibition
01 Nov 2021 //
BUSINESSWIRE
Rheos Medicines Forms Research Collaboration With CRYOSTEM to Evaluate MALT1
27 Oct 2021 //
BUSINESSWIRE
A joint patent application for MALT1 inhibitors published
15 Oct 2021 //
BIOSPACE
Rheos Medicines to Present Data at ACR 2021 for MALT1 Inhibitors
13 Oct 2021 //
BUSINESSWIRE
Rheos Medicines Appoints Nirupama Subramanian as Chief Operating Officer
09 Aug 2021 //
BUSINESSWIRE
Rheos Medicines Appoints Industry Leader, John Davis, Jr
12 Jul 2021 //
BUSINESSWIRE
Rheos Medicines and PatientsLikeMe Announce Strategic Collaboration
17 Dec 2020 //
PRNEWSWIRE
Rheos Medicines Announces Worldwide Collaboration with Roche
19 Dec 2019 //
BUSINESS WIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.